Delpha Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Delpha Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30	Closed	-$3K	–	379
2017 Q4	$3K	Buy	+30	New	+$3K	﹤0.01%	1408

Other funds holding CTXR

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HFM

Hartford Financial Management Hartford, Connecticut $448M AUM 32.11% 1-Year Est. Return

Delpha Capital Management's CTXR Position: Q1 2018 in Review

Delpha Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2018, closing a stake of 30 shares — an estimated $3K sold.

Delpha Capital Management first reported a position in CTXR in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 6 funds tracked by Wall St. Rank hold CTXR as of Q1 2018.

Delpha Capital Management reported no remaining Citius Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 30 Citius Pharmaceuticals shares in Q1 2018, an estimated $3K.
Delpha Capital Management first reported a position in Citius Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's Citius Pharmaceuticals position peaked at $3K in Q4 2017.
6 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.